Characterization of MBT-2 tumour cell "variant" resistant to tumour necrosis factor
- PMID: 2028563
- DOI: 10.1007/BF00294024
Characterization of MBT-2 tumour cell "variant" resistant to tumour necrosis factor
Abstract
Previously we reported sensitivity of MBT-2 murine bladder tumour to tumour necrosis factor (TNF) in vivo and in vitro [8]. We showed that with prolonged exposure of cultured MBT-2 tumour cells to TNF, a resistant MBT-2 "variant" tumour cell population emerged in vitro. This concurred with the finding of transient in vivo cytotoxic effect of TNF against MBT-2 tumour. Herein, we delineate phenotypic changes in MBT-2 cells associated with TNF resistance. Parent MBT-2 (MBT-2P) and the TNF-resistant "variant" MBT-2R cells were compared in terms of in vitro sensitivity to TNF, DNA profile, karyotype and in vitro growth kinetics. We conclude that acquisition of resistance to TNF may be due to cell cycle derangement and differences in in vitro growth characteristics. DNA indices and karyotype of "variant" MBT-2R cells were not altered, indicating the anti-tumour action of TNF is not-mutagenic.
Similar articles
-
Concomitant treatment of MBT-2 bladder tumour by tumour necrosis factor alpha and interferon alpha in conjunction with delayed type hypersensitivity immunotherapy.Urol Res. 1991;19(1):57-62. doi: 10.1007/BF00294023. Urol Res. 1991. PMID: 1674182
-
Anti-tumor effect of tumor necrosis factor and its induction of tumor variant of MBT-2 transitional cell carcinoma of the bladder.J Urol. 1988 May;139(5):1091-4. doi: 10.1016/s0022-5347(17)42793-5. J Urol. 1988. PMID: 3361654
-
In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2).J Urol. 1990 Jul;144(1):172-5. doi: 10.1016/s0022-5347(17)39404-1. J Urol. 1990. PMID: 2113589
-
[Low-grade and low-stage transitional carcinoma of the bladder. Review].Actas Urol Esp. 1985 May-Jun;9(3):203-8. Actas Urol Esp. 1985. PMID: 3898736 Review. Spanish. No abstract available.
-
Bladder tumours in children.Prog Clin Biol Res. 1984;162B:289-301. Prog Clin Biol Res. 1984. PMID: 6390449 Review. No abstract available.
Cited by
-
Concomitant treatment of MBT-2 bladder tumour by tumour necrosis factor alpha and interferon alpha in conjunction with delayed type hypersensitivity immunotherapy.Urol Res. 1991;19(1):57-62. doi: 10.1007/BF00294023. Urol Res. 1991. PMID: 1674182
References
MeSH terms
Substances
LinkOut - more resources
Medical